Gene-Edited 'Living Drug' trial seeks to reboot immune system against tough cancers
NCT ID NCT07297160
Summary
This is an early safety study for people with advanced lymphoma, myeloma, or certain solid tumors (like kidney cancer and sarcoma) that have come back after standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack cancer cells carrying a marker called CD70, and then infuse them back into the patient. The main goals are to find a safe dose, understand side effects, and see if this approach shows signs of helping control these difficult cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
The Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.